Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21661017 | 0.80 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KDM1ACTSL | |
| SCHEMBL20656041 | 0.79 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL27055532 | 0.75 | BCHE (0.39) | SLC6A2SLC6A4SLC6A3KDM1AKDM4E | |
| SCHEMBL21402585 | 0.74 | CTSK (0.40) | CTSLCTSBCTSHCTSK | |
| SCHEMBL24428835 | 0.74 | SMN1; SMN2 (0.48) | MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL20656066 | 0.71 | HRH3 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25804761 | 0.70 | HRH3 (0.36) | SLC6A2SLC6A4SLC6A3KDM1AKDM4E | |
| SCHEMBL24925644 | 0.70 | HTR1A (0.43) | KDM1A | |
| SCHEMBL24461609 | 0.69 | KDM1A (0.39) | SLC6A2SLC6A4SLC6A3KDM1AKDM4E | |
| SCHEMBL27051363 | 0.69 | KDM1A (0.39) | SLC6A2SLC6A4SLC6A3KDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SLC6A2 3857/4885SLC6A4 3003/4885SLC6A3 3731/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | SLC6A2 3857/4885SLC6A4 3003/4885SLC6A3 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.